Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:59:19.579Z.
Calculation as of: 2026-10-06T19:59:19.579Z.
Quote observation: 2026-10-06T19:55:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b7fd3b5d8e417d78924f6cd313032c2aac5600bd184120b35a4860f29c1b1599
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$69.88M
EBITDA Yield
0.38%
TTM Avg
3.41%
3Y Avg
4.41%
5Y Avg
3.27%
Market Cap
$68.61M
EBITDA Yield
30.31%
TTM Avg
26.76%
3Y Avg
678.75%
5Y Avg
678.75%
Market Cap
$65.86M
EBITDA Yield
445.09%
TTM Avg
3466.62%
3Y Avg
3466.62%
5Y Avg
3466.62%
Market Cap
$72.83M
EBITDA Yield
N/A
TTM Avg
0.69%
3Y Avg
0.69%
5Y Avg
0.69%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tiziana Life Sciences Ltd (TLSA) | $69.36M | N/A | N/A | N/A | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $69.88M | 0.38% | 3.41% | 4.41% | 3.27% |
| Fortress Biotech, Inc. (FBIO)vs › | $68.10M | N/A | N/A | N/A | N/A |
| Spero Therapeutics, Inc. (SPRO)vs › | $68.61M | 30.31% | 26.76% | 678.75% | 678.75% |
| Gain Therapeutics, Inc. (GANX)vs › | $71.23M | N/A | N/A | N/A | N/A |
| iBio, Inc. (IBIO)vs › | $67.52M | N/A | N/A | N/A | N/A |
| Cingulate Inc. (CING)vs › | $65.86M | 445.09% | 3466.62% | 3466.62% | 3466.62% |
| MindWalk Holdings Corp. (HYFT)vs › | $72.83M | N/A | 0.69% | 0.69% | 0.69% |
| XBiotech Inc. (XBIT)vs › | $66.01M | N/A | N/A | N/A | N/A |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $71.64M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
